Join an observational pregnancy study on eczema
Help future moms and babies by enrolling into our ADBRY™ (tralokinumab) & Pregnancy study!
MotherToBaby is currently enrolling pregnant people in an observational study examining the use of ADBRY™ (tralokinumab) to treat moderate-to-severe eczema (atopic dermatitis) when taken during pregnancy. If you’ve taken ADBRY™ and are pregnant, you may qualify for this important study.
Our study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your and your baby’s medical records from your healthcare providers.
• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor
• A neurodevelopmental assessments that can also provide insight into the child’s development at approximately 4 months and 12 months of age
“Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our ADBRY™ & Pregnancy Study.”
— Christina Chambers, PhD, MPH, MotherToBaby Pregnancy Studies
MotherToBaby is the most trusted information source for medication safety in pregnancy.
If you have moderate-to-severe eczema and are pregnant, you may qualify to join this important study!
Join our ADBRY™ Study
Your information is confidential.
MotherToBaby Pregnancy Studies are conducted by the Organization of Teratology Information Specialists (OTIS) and coordinated by the University of California San Diego. MotherToBaby is listed as a resource for information about medications in pregnancy by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).